• Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer

  • 2024/12/19
  • 再生時間： 20 分
  • ポッドキャスト

Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who receive stem cell transplants, and a cell death process that may help account for increased thromboembolic risk in patients receiving cancer chemotherapy.

    Featured Articles:

    • Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
    • Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism
    • GSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential
    続きを読む 一部表示

あらすじ・解説

In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who receive stem cell transplants, and a cell death process that may help account for increased thromboembolic risk in patients receiving cancer chemotherapy.

Featured Articles:

  • Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
  • Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism
  • GSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential
続きを読む 一部表示

Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancerに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。